Viva Biotech Holdings

SEHK:1873 Stock Report

Market Cap: HK$3.0b

Viva Biotech Holdings Future Growth

Future criteria checks 4/6

Viva Biotech Holdings is forecast to grow earnings and revenue by 26.1% and 14.2% per annum respectively.

Key information

26.1%

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth31.6%
Revenue growth rate14.2%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Apr 2025

Recent future growth updates

No updates

Recent updates

Viva Biotech Holdings (HKG:1873) Strong Profits May Be Masking Some Underlying Issues

May 01
Viva Biotech Holdings (HKG:1873) Strong Profits May Be Masking Some Underlying Issues

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Apr 25
Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Viva Biotech Holdings' (HKG:1873) Shares Bounce 29% But Its Business Still Trails The Industry

Mar 30
Viva Biotech Holdings' (HKG:1873) Shares Bounce 29% But Its Business Still Trails The Industry

Viva Biotech Holdings' (HKG:1873) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Feb 12
Viva Biotech Holdings' (HKG:1873) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Oct 14
Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Aug 30
Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03
Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26
A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11
Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Dec 23
Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Nov 06
Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Jun 13
Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Apr 17
We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13
Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06
Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02
What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21
Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Earnings and Revenue Growth Forecasts

SEHK:1873 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,032412N/AN/A1
12/31/20262,628345N/AN/A1
12/31/20252,248288N/AN/A1
12/31/20241,987167182374N/A
9/30/20241,9918393296N/A
6/30/20241,99503218N/A
3/31/20242,075-5899301N/A
12/31/20232,156-116196383N/A
9/30/20232,284-276296497N/A
6/30/20232,413-436396611N/A
3/31/20232,396-482266498N/A
12/31/20222,380-528137386N/A
9/30/20222,283-209-96269N/A
6/30/20222,186111-329152N/A
3/31/20222,145199-409115N/A
12/31/20212,104288-48878N/A
9/30/20211,815258-61959N/A
6/30/20211,526228-75040N/A
3/31/20211,111-79-66242N/A
12/31/2020697-387-57543N/A
9/30/2020538-349-30849N/A
6/30/2020378-311-4154N/A
3/31/2020351-23-2850N/A
12/31/2019323266-1646N/A
9/30/2019299176-2731N/A
6/30/201927586-3916N/A
3/31/201924388-3714N/A
12/31/201821091-3512N/A
12/31/201714876N/A28N/A
12/31/20169624N/A21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1873's forecast earnings growth (26.1% per year) is above the savings rate (2.4%).

Earnings vs Market: 1873's earnings (26.1% per year) are forecast to grow faster than the Hong Kong market (10.4% per year).

High Growth Earnings: 1873's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1873's revenue (14.2% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 1873's revenue (14.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1873's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/10 02:09
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viva Biotech Holdings is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Dennis IpDaiwa Securities Co. Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.